A 28-week, randomized, double-blind, active-controlled, multicenter study to evaluate the efficacy of subcutaneously administered secukinumab compared to ustekinumab in adult patients with psoriatic arthritis and failure of TNFα-inhibitor treatment (AgAIN)
Latest Information Update: 21 Oct 2025
At a glance
- Drugs Secukinumab (Primary) ; Ustekinumab
 - Indications Plaque psoriasis; Psoriatic arthritis
 - Focus Therapeutic Use
 - Acronyms AgAIN
 - Sponsors Novartis Pharma
 
Most Recent Events
- 13 Dec 2024 Status changed to completed.
 - 06 Dec 2024 Status changed from active, no longer recruiting to discontinued. (Project discontinued to prioritize other key programs in portfolio)
 - 09 Aug 2024 Planned primary completion date changed from 31 Jul 2024 to 15 Oct 2024.